Drug Profile
SDZ NDD 094
Alternative Names: NDD 094Latest Information Update: 28 Sep 2001
Price :
$50
*
At a glance
- Originator Novartis
- Class Neuroprotectants; Nootropics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Sep 2001 No-Development-Reported for Alzheimer's disease in Switzerland (PO)
- 28 Sep 2001 No-Development-Reported for Alzheimer's disease in USA (PO)
- 22 Nov 1999 Phase-II clinical trials for Alzheimer's disease in Switzerland (PO)